TECHNICAL
DATA
SHEET

Fluorescent Imaging Agent
Caution: For Laboratory Use. A product for research purposes only.

IntegriSense™ 750
Product Number: NEV10873

DESCRIPTION: IntegriSense™ 750 is a targeted fluorescence imaging agent comprising a potent, selective non-peptide

small molecule integrin αvβ3 antagonist and a near-infrared (NIR) fluorochrome. This agent has been developed to enable invivo visualization and quantification of integrin αvβ3 expressed in tumor cells as well as in neovasculature, to monitor tumor
growth, tumor angiogenesis, and treatment efficacy. Half-life of IntegriSense 750 signal in tissue is approximately four days

MATERIAL (Needs to be reconstituted)

CONTENTS: Each vial contains 24 nmol of IntegriSense
750 lyophilized solid. The IntegriSense 750 solution has been
filtered through a 0.2 µm filter prior to lyophilization.
Reconstitute IntegriSense 750 with 1.2 mL of 1 x PBS before
injecting into animals. The packaged material provides
sufficient reagent for imaging approximately 10 mice (weighing~25 grams each) when using the recommended dose of 2 nmol(100 µL) of IntegriSense 750 per mouse.

Table 1. IntegriSense 750 Characteristics
Property
Specification
MW1278 g mol-1
1Fluorescence Excitation
755 nm Emission
775 nmAbsorbance
748 nmPurity2>95 %Appearance
Dark blue-green
solid

1. Absorbance and fluorescence maxima of IntegriSense 750 in 1x PBS.
2. As determined by RP-HPLC and measuring absorbance at 750 nm.

PROPERTIES: The physical characteristics ofIntegriSense 750 can be found in Table 1 andFigure 1.

Fig 1.

STORAGE & HANDLING:
Page 1 of 2Upon receipt, IntegriSense 750 should beIMMEDIATELY STORED AT 2-8 oC ANDPROTECTED FROM LIGHT.
When stored and handled properly, IntegriSense
750 is stable for up to twelve months in thelyophilized form.
Before opening the vial check to ensure that thelyophilized powder is present at the bottom of the vial.
After reconstituting with PBS, gently swirl the solution to ensure that the lyophilized powder is fully in solution.
Once reconstituted with 1 x PBS, the solution is stable up to 10 days when stored at 2-8 ºC and protectedfrom light.

IN VIVO IMAGING AND APPLICATIONS:

The generally recommended procedure for in vivo imaging with IntegriSense 750 is administration via intravenous
injection and imaging 24 hours post injection.
Imaging may be performed as early as 6 hours with some reduction in target signal/noise.
IntegriSense 750 will clear from tissues after ~5 days. Repeat injection and imaging may be performed every
five days for longitudinal studies. It is recommended that a pre-injection baseline image be taken prior toreinjection and imaging.
IntegriSense 750 enables imaging of tumors and neovasculature in a range of oncology applications.

NOTES:
PerkinElmer’s IntegriSense 750 is intended for research purposes only and is not for human use. It must be used byor directly under the supervision of a technically qualified individual experienced in handling potentially hazardous
materials. Please read the Material Safety Data Sheet (MSDS) provided for this product.

Several of PerkinElmer’s products and product applications are covered by U.S and foreign patents and patents
pending. Our products are not available for resale or other commercial uses without a specific agreement from
PerkinElmer.

PerkinElmer, Inc.
549 Albany Street
Boston, MA 02118 USA
P: (800) 762-4000 or (+1) 203-925-4602
www.perkinelmer.com/nenradiochemicals
For a complete listing of our global offices, visit www.perkinelmer.com/ContactUs
Copyright ©2010, PerkinElmer, Inc. All rights reserved. PerkinElmer® is a registered trademark of PerkinElmer, Inc.
All other trademarks are the property of their respective owners.